Dr. Brian Helfand

Dr. Brian Helfand
Brian Helfand, MD, PhD, is Chief of the Division of Urology and the Ronald L. Chez Family and Richard Melman Family Endowed Chair at NorthShore University HealthSystem. He is Director of the Personalized Prostate Program and Director of the Clinical Research Program. He is also an active surgeon who is involved in the care of this patients with prostate issues including benign prostatic hyperplasia. His clinical care and research programs are focused on implementation of personalized treatment plans that include providing therapies that are suited for their specific needs. As such, Dr. Helfand was an early adopter of Aquablation therapy to help relieve bothersome lower urinary tract symptoms for men with benign prostatic hyperplasia. Dr. Helfand completed his undergraduate degree at Emory University. He received his medical training and PhD in Cell and Molecular Biology and Genetics from Northwestern University. He is fellowhip trained in urologic oncology. He was recruited in 2011 from Northwestern University’s Feinberg School of Medicine, where he was faculty in the Department of Urology. Dr. Helfand is an internationally-recognized urologist and translational researcher. He has received multiple grants from the National Institute of Health and has published over 180 peer-reviewed manuscripts in prestigious journals including Nature Genetics, The Journal of Cell Biology, The Journal of Urology and Science Translational Medicine. Dr. Helfand is involved in national and international collaborative networks including the Lower Urinary Tract Dysfunction Network (LURN).

Locations

Northshore Medical Group Glenview, IL

2180 Pfingsten Road, Ste 3000Glenview, Illinois, 60026United States
847-503-3000 | Visit Website

All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.

Rx Only